These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 18955526)

  • 1. Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
    Finegold SM; Molitoris D; Väisänen ML
    Antimicrob Agents Chemother; 2009 Jan; 53(1):281-6. PubMed ID: 18955526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
    Marchese A; Salerno A; Pesce A; Debbia EA; Schito GC
    Chemotherapy; 2000; 46(4):253-66. PubMed ID: 10859431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
    Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria.
    Lamanna A; Orsi A
    Chemioterapia; 1984 Dec; 3(6):365-7. PubMed ID: 6529778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of ampicillin/sulbactam against cefoxitin-resistant anaerobic bacteria.
    Jones RN; Barry AL
    J Antimicrob Chemother; 1988 Jan; 21(1):135-8. PubMed ID: 3356620
    [No Abstract]   [Full Text] [Related]  

  • 6. [Comparative in vitro activity of ampicillin, cefoperazone and their combinations with sulbactam, as well as that of other antibiotics against anaerobic organisms].
    Rezvan SP; Sidorenko SV; Budanov SV
    Antibiot Khimioter; 1995 Apr; 40(4):25-9. PubMed ID: 7654095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of vancomycin and teicoplanin against anaerobic bacteria.
    Robbins MJ; Marais R; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1987; 13(9):551-4. PubMed ID: 2962846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ampicillin plus sulbactam in vitro activity against anaerobes.
    Heilmann F; Heizmann W; Werner H
    Drugs; 1988; 35 Suppl 7():84-8. PubMed ID: 3220012
    [No Abstract]   [Full Text] [Related]  

  • 9. [The effect of a combination of ampicillin and sulbactam against clinical anaerobic isolates].
    Werner H; Heizmann W; Heilmann F
    Arzneimittelforschung; 1988 Jul; 38(7):866-8. PubMed ID: 3207432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broth-disk elution tests to predict the susceptibility of anaerobic bacteria to the ampicillin-sulbactam combination.
    Jones RN
    Diagn Microbiol Infect Dis; 1990; 13(4):353-5. PubMed ID: 2076598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association experiments in antimicrobial susceptibility testing of aerobes and anaerobes to ampicillin and ampicillin plus sulbactam.
    Heizmann WR; Werner H; Heilmann F
    J Chemother; 1989 Jul; 1(4 Suppl):315-6. PubMed ID: 16312418
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp.
    Ripa S; Mignini F; Prenna M; Falcioni E
    Drugs Exp Clin Res; 1987; 13(8):483-8. PubMed ID: 3428130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding to and antibacterial effect of ampicillin, neomycin and polymyxin B on human faeces.
    Hazenberg MP; Pennock-Schröder AM; Van den Boom M; Van de Merwe JP
    J Hyg (Lond); 1984 Aug; 93(1):27-34. PubMed ID: 6086749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin--a novel antimicrobial for enteric infections.
    Huang DB; DuPont HL
    J Infect; 2005 Feb; 50(2):97-106. PubMed ID: 15667909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
    Schumacher U; Manncke B; Gerbracht K; Werner H
    Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of teicoplanin, vancomycin, A16686, clindamycin, erythromycin and fusidic acid against anaerobic bacteria.
    Hassan H; O'Hare MD; Felmingham D
    Singapore Med J; 1990 Feb; 31(1):56-8. PubMed ID: 2139737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii.
    Punpanich W; Munsrichoom A; Srisarang S; Treeratweeraphong V
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S95-100. PubMed ID: 22043760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacteriology of 100 consecutive diabetic foot infections and in vitro susceptibility to ampicillin/sulbactam versus cefoxitin.
    Borrero E; Rossini M
    Angiology; 1992 Apr; 43(4):357-61. PubMed ID: 1558322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A combination of ampicillin and sulbactam: effect on aerobic and anaerobic gram-negative bacteria].
    González C; García A; Urrea R; del Solar E; Bello H; Zemelman R
    Rev Med Chil; 1990 May; 118(5):548-54. PubMed ID: 2293275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The susceptibility of Helicobacter pylori to the rifamycin, rifaximin.
    Holton J; Vaira D; Menegatti M; Barbara L
    J Antimicrob Chemother; 1995 Apr; 35(4):545-9. PubMed ID: 7628989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.